Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

702
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
702

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of ellagic acid on BDNF/PI3K/AKT-mediated signaling pathways in mouse models of depression.

Iranian journal of basic medical sciences·2025
Same author

Does Resveratrol Prevent Sevoflurane Toxicity in Newborn Rats?

Journal of medicinal food·2022
Same author

The antidepressant-like activity of ellagic acid and its effect on hippocampal brain derived neurotrophic factor levels in mouse depression models.

Natural product research·2017
Same author

Update on pharmacological treatment of acute coronary syndrome without persistent ST segment elevation myocardial infarction in the elderly.

Journal of geriatric cardiology : JGC·2017
Same author

Ellagic acid reduces L-type Ca2+ current and contractility through modulation of NO-GC-cGMP pathways in rat ventricular myocytes.

Journal of cardiovascular pharmacology·2014
Same author

The pharmacological use of ellagic acid-rich pomegranate fruit.

International journal of food sciences and nutrition·2013

Related Experiment Video

Updated: Mar 16, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.0K

How abciximab might be clinically useful.

Coşkun Usta1, Nur Tükel Turgut1, Aslı Bedel1

  • 1Department of Pharmacology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.

International Journal of Cardiology
|August 14, 2016
PubMed
Summary

Glycoprotein (GP) IIb/IIIa inhibitors were vital for acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). Current therapy shifts away from these agents due to effectiveness and adverse effects, necessitating careful benefit-harm evaluation.

Keywords:
AbciximabAcute coronary syndromesPlatelet aggregation

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

Related Experiment Videos

Last Updated: Mar 16, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Platelet aggregation, mediated by glycoprotein (GP) IIb/IIIa receptors, is central to coronary artery thrombus formation.
  • GP IIb/IIIa inhibitors (GPI) significantly reduced ischemic complications in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI) since the late 1990s.

Purpose of the Study:

  • To review the role and current standing of GP IIb/IIIa inhibitors, specifically abciximab, in managing ACS and PCI.
  • To discuss the evolving therapeutic landscape and the reasons for the shift away from GPIs in ST-segment elevation myocardial infarction (STEMI).

Main Methods:

  • Literature review focusing on the clinical application and outcomes of GP IIb/IIIa inhibitors.
  • Detailed examination of abciximab's efficacy and safety profile.
  • Comparative analysis of GPIs with alternative therapeutic agents.

Main Results:

  • While GPIs demonstrated clear clinical benefits, particularly in PCI during ACS (NSTE-ACS and STEMI), their use has declined in STEMI therapy.
  • Factors contributing to this shift include evolving treatment strategies, concerns about effectiveness, and potential adverse effects like thrombocytopenia and bleeding.
  • Variability exists among GPIs, with abciximab being the focus of this review.

Conclusions:

  • The therapeutic utility of potent agents like GP IIb/IIIa inhibitors requires a careful balance of benefits and harms.
  • Ongoing evaluation is necessary to optimize treatment strategies for ACS and PCI, considering both efficacy and safety profiles.